1. Home
  2. BMR vs PASG Comparison

BMR vs PASG Comparison

Compare BMR & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beamr Imaging Ltd.

BMR

Beamr Imaging Ltd.

HOLD

Current Price

$1.67

Market Cap

26.9M

Sector

Technology

ML Signal

HOLD

PASG

Passage Bio Inc.

HOLD

Current Price

$7.64

Market Cap

26.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMR
PASG
Founded
2009
2017
Country
Israel
United States
Employees
N/A
27
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.9M
26.0M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
BMR
PASG
Price
$1.67
$7.64
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$23.50
AVG Volume (30 Days)
43.1K
30.3K
Earning Date
01-01-0001
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.54
$0.28
52 Week High
$4.32
$20.00

Technical Indicators

Market Signals
Indicator
BMR
PASG
Relative Strength Index (RSI) 44.65 37.40
Support Level $1.57 $6.71
Resistance Level $2.10 $7.72
Average True Range (ATR) 0.13 0.77
MACD 0.01 0.02
Stochastic Oscillator 28.21 16.73

Price Performance

Historical Comparison
BMR
PASG

About BMR Beamr Imaging Ltd.

Beamr Imaging Ltd is a video technology and image science software company. It is an innovator of video encoding, transcoding, and optimization solutions that enable high quality, performance, and unmatched bitrate efficiency for video and images. The company is conducted through one operating segment, the optimization technology for video and photo compression. The company operates in Israel, the United States, and the rest of the world, it derives a majority of its revenue from the United States.

About PASG Passage Bio Inc.

Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.

Share on Social Networks: